Table 1.
Experimental design
| Experiment | Vaccine | # animals | Vaccination time (dpv) [route, vol.] | Challenge (dpv) | BoHV-1 antibodies (dpv) | BoHV-1 sheeding (dpv/dpc) | LPT (dpv/dpc) |
|---|---|---|---|---|---|---|---|
| inactivated BoHV-1ΔgEβgal vaccine |
BoHV-1ΔgEβgal |
5 |
0, 21 [SC, 3 ml] |
186 |
0, 14, 21, 30, 67, 150 and 186 |
0, 3, 5, 7, 8, 10, 12, 14, 17 and 22 dpc |
7,72 dpv |
| BoHV-1LA |
5 |
0, 21 [SC, 3 ml] |
186 |
||||
| mock |
6 |
186 |
|||||
| |
|
||||||
| attenuated BoHV-1ΔgEβgal vaccine |
BoHV-1ΔgEβgal |
5 |
Group 1: 0 [IN, 4 ml] |
42 |
0, 7, 19, 34 and 42 |
1 to 42dpv |
7,30 dpc |
| |
5 |
Group 2: 0 [IM, 4 ml] |
42 |
|
and |
||
| Sentinel |
5 |
Group 4 |
|
|
3, 5, 7, 8, 10, 12, 14, 17 and 22 dpc |
||
| Mock |
5 |
Group 5 |
42 |
|
|||
| attenuated BoHV-1ΔgEβgal vaccine SAFETY | BoHV-1ΔgEβgal | 5 | Group 3: 0 [IV, 4 ml] | along 370 |
SC: subcutaneous, dpv: days post-vaccination; dpc: days post-challenge.
During the next 42 days post- vaccination with attenuated BoHV-1ΔgEβgal, viral excretion was controlled, as well as clinical signs such as loss of appetite, lesions of nasal, ocular and oral mucosae and discharge from the nose or eyes and rectal temperature. General clinical status was evaluated and recorded using a rating system (ranging from 0 = asymptomatic to 3 = severe symptoms). Nasal swabs were scored as follows: 0 = absent, 1 = slightly serous, 2 = severely serous, 3 = seromucous, 4 = mucopurulent.